By 1812 the U.S. already had more business corporations than any other country, and possibly more than all other countries put together, securing its role as the world’s first “corporation nation.”

By Richard Sylla and Robert E. Wright

Sensitivity of investment and valuation to drug price indices and market conditions

By Cody Hyman, Henry Dao, Gregory Vaughan, and Fred Ledley

The concentration of innovation in a handful of urban centers engenders large and persistent regional disparities in economic opportunity.

By Aakash Kalyani, Nicholas Bloom, Marcela Carvalho, Tarek Alexander Hassan, Josh Lerner, and Ahmed Tahoun

The current paper returns to the key questions of wages and incomes and how wealth effects cripple reliance on interest rates to control inflation.

By Thomas Ferguson and Servaas Storm

How convincing is the model analysis by Bernanke and Blanchard? How empirically relevant are their mechanisms causing inflation – and how robust and plausible are their econometric findings?

By Servaas Storm

The empirical analysis of public sector investments and the health value created by the drugs selected for Medicare price negotiations provides a cost basis for the assessment of the maximum fair price.

By Edward W. Zhou, Paula G. Chaves da Silva, Debbie Quijada, and Fred Ledley